JP2017537985A5 - - Google Patents

Download PDF

Info

Publication number
JP2017537985A5
JP2017537985A5 JP2017550469A JP2017550469A JP2017537985A5 JP 2017537985 A5 JP2017537985 A5 JP 2017537985A5 JP 2017550469 A JP2017550469 A JP 2017550469A JP 2017550469 A JP2017550469 A JP 2017550469A JP 2017537985 A5 JP2017537985 A5 JP 2017537985A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
plga
composition according
polymer
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017550469A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537985A (ja
JP6882186B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/065894 external-priority patent/WO2016100392A1/en
Publication of JP2017537985A publication Critical patent/JP2017537985A/ja
Publication of JP2017537985A5 publication Critical patent/JP2017537985A5/ja
Priority to JP2021078406A priority Critical patent/JP2021119183A/ja
Application granted granted Critical
Publication of JP6882186B2 publication Critical patent/JP6882186B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017550469A 2014-12-15 2015-12-15 スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法 Active JP6882186B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021078406A JP2021119183A (ja) 2014-12-15 2021-05-06 スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462092118P 2014-12-15 2014-12-15
US62/092,118 2014-12-15
US201562139306P 2015-03-27 2015-03-27
US62/139,306 2015-03-27
PCT/US2015/065894 WO2016100392A1 (en) 2014-12-15 2015-12-15 Sunitinib formulations and methods for use thereof in treatment of ocular disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021078406A Division JP2021119183A (ja) 2014-12-15 2021-05-06 スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法

Publications (3)

Publication Number Publication Date
JP2017537985A JP2017537985A (ja) 2017-12-21
JP2017537985A5 true JP2017537985A5 (cg-RX-API-DMAC7.html) 2019-01-31
JP6882186B2 JP6882186B2 (ja) 2021-06-02

Family

ID=55069169

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017550469A Active JP6882186B2 (ja) 2014-12-15 2015-12-15 スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法
JP2017550467A Active JP6847848B2 (ja) 2014-12-15 2015-12-15 スニチニブ製剤、及び緑内障の治療におけるその使用方法
JP2021078406A Pending JP2021119183A (ja) 2014-12-15 2021-05-06 スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017550467A Active JP6847848B2 (ja) 2014-12-15 2015-12-15 スニチニブ製剤、及び緑内障の治療におけるその使用方法
JP2021078406A Pending JP2021119183A (ja) 2014-12-15 2021-05-06 スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法

Country Status (19)

Country Link
US (4) US10525034B2 (cg-RX-API-DMAC7.html)
EP (3) EP3233058A1 (cg-RX-API-DMAC7.html)
JP (3) JP6882186B2 (cg-RX-API-DMAC7.html)
KR (2) KR20170094793A (cg-RX-API-DMAC7.html)
CN (3) CN117398350A (cg-RX-API-DMAC7.html)
AU (2) AU2015362621B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017012706A2 (cg-RX-API-DMAC7.html)
CA (1) CA2972075C (cg-RX-API-DMAC7.html)
CO (1) CO2017007003A2 (cg-RX-API-DMAC7.html)
EA (1) EA201791337A1 (cg-RX-API-DMAC7.html)
HK (1) HK1243942A1 (cg-RX-API-DMAC7.html)
IL (1) IL252943A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017007873A (cg-RX-API-DMAC7.html)
NZ (1) NZ733130A (cg-RX-API-DMAC7.html)
PH (1) PH12017501097A1 (cg-RX-API-DMAC7.html)
RU (1) RU2729731C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201903210WA (cg-RX-API-DMAC7.html)
WO (2) WO2016100380A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201703875B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
WO2013134766A2 (en) * 2012-03-09 2013-09-12 The Johns Hopkins University Identification of molecular pathways and methods of use thereof for treating retinal neurodegeneration and other neurodegenerative disorders
SG10201903210WA (en) * 2014-12-15 2019-05-30 Univ Johns Hopkins Sunitinib Formulations and Methods for Use Thereof in Treatment of Ocular Disorders
US9808531B2 (en) 2015-09-22 2017-11-07 Graybug Vision, Inc. Compounds and compositions for the treatment of ocular disorders
HK1257499A1 (zh) 2015-11-12 2019-10-25 Graybug Vision, Inc. 用於治疗的聚集性微粒
AU2018240462C1 (en) 2017-03-23 2022-12-08 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
WO2018182527A1 (en) * 2017-03-30 2018-10-04 National University Of Singapore Method for treating inflammatory complications in eye diseases
MX2019013363A (es) 2017-05-10 2020-01-13 Graybug Vision Inc Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
EP3654950A4 (en) * 2017-07-17 2021-04-21 Wolfcreek Biotech Pte Ltd MICROPARTICLE FORMULATIONS FOR THE DELIVERY OF ACTIVE INGREDIENTS
JP2021529747A (ja) * 2018-06-25 2021-11-04 タイタン ファーマシューティカルズ インコーポレイテッド 親油性又は両親媒性医薬物質の放出のためのインプラント
CN112566625A (zh) * 2018-08-18 2021-03-26 夫特弗制药私人有限公司 口服剂量的化学治疗药物悬浮液
CN110946858A (zh) * 2018-09-27 2020-04-03 中国科学院上海生命科学研究院 吲哚满酮衍生物在治疗肥胖及其相关疾病中的应用
WO2020069353A1 (en) * 2018-09-27 2020-04-02 Graybug Vision, Inc. Compounds and compositions for ocular delivery
KR102322429B1 (ko) * 2018-10-31 2021-11-08 주식회사 삼양홀딩스 수니티닙을 함유하는 경구용 제제 및 그의 제조 방법
KR102308227B1 (ko) * 2018-10-31 2021-10-05 주식회사 삼양홀딩스 수니티닙을 함유하는 경구용 정제 조성물
AU2019379607A1 (en) * 2018-11-15 2021-06-03 Graybug Vision, Inc. Improved aggregated microparticles
KR102442103B1 (ko) * 2019-04-30 2022-09-08 주식회사 엘지화학 캐스파제 저해제의 프로드럭
US11471412B1 (en) * 2019-05-10 2022-10-18 University Of South Florida Nanoparticles and nanogel drug compositions for treatment of age-related macular degeneration
CN110833425B (zh) * 2019-11-27 2022-12-30 佛山科学技术学院 一种用于鸡胚采血的血管托持器
CA3163892A1 (en) * 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye
WO2021113651A2 (en) * 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery
KR20240025990A (ko) * 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물
KR20240028815A (ko) 2022-08-25 2024-03-05 주식회사 스카이테라퓨틱스 약리 활성 물질의 신규 분자회합체 및 이를 포함하는 약학 조성물
WO2024095026A1 (en) 2022-11-04 2024-05-10 Semmelweis Egyetem In vivo targeting of therapeutic molecules to the retina via the optical system of the eye

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB929405A (en) 1958-12-22 1963-06-19 Upjohn Co Processes for the encapsulation of particles
GB929401A (en) 1958-12-22 1963-06-19 Upjohn Co Encapsulated emulsions and processes for their preparation
GB969808A (en) 1962-06-08 1964-09-16 Boots Pure Drug Co Ltd Anthelmintic compositions and compounds
IT1148784B (it) 1980-04-09 1986-12-03 Eurand Spa Procedimento per la preparazione di microcapsule in un veicolo liquido
US4794000A (en) 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4991920A (en) 1988-12-27 1991-02-12 Andrzej Peczalski Optical converter
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5441722A (en) 1994-02-18 1995-08-15 Merck & Co., Inc. Short synthesis of 5,6-dihydro-(S)-4-(ethylamino)-(S)-6-[C3 H3 ]-4[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide and related non radioactive compounds
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
JPH10511957A (ja) 1995-01-05 1998-11-17 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ ミシガン 表面改質ナノ微粒子並びにその製造及び使用方法
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6841617B2 (en) 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
US6703047B2 (en) 2001-02-02 2004-03-09 Incept Llc Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use
US6818018B1 (en) 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
US6632457B1 (en) 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
JP2002531217A (ja) 1998-12-04 2002-09-24 チャンドラシェカー ピー. パサック, 生体適合性架橋ポリマー
US20040258763A1 (en) 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
ES2382636T3 (es) 2000-10-31 2012-06-12 Surmodics Pharmaceuticals, Inc. Método para producir composiciones para la administración mejorada de moléculas bioactivas
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US7060299B2 (en) 2002-12-31 2006-06-13 Battelle Memorial Institute Biodegradable microparticles that stabilize and control the release of proteins
US20070122487A1 (en) * 2003-03-19 2007-05-31 University Of Kentucky Research Foundation (Poly(acryloyl-hydroxyethyl starch)-plga composition microspheres
GB0307011D0 (en) 2003-03-27 2003-04-30 Regentec Ltd Porous matrix
CN101862455A (zh) 2003-06-26 2010-10-20 普西维达公司 原位胶凝的药物递送系统
US20090148527A1 (en) 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
WO2005072710A2 (en) 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
EP1931387A4 (en) * 2005-09-07 2012-07-11 Southwest Res Inst BIODEGRADABLE MICROTEILED PHARMACEUTICAL FORMULATIONS WITH IMPROVED RELEASE RATES
US7501179B2 (en) 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles
JP2009521493A (ja) 2005-12-23 2009-06-04 アルコン,インコーポレイテッド 眼への受容体チロシンキナーゼ阻害(RTKi)化合物の送達のための医薬製剤
EP1986603A2 (en) 2006-01-13 2008-11-05 SurModics, Inc. Microparticle containing matrices for drug delivery
US20080166411A1 (en) 2006-04-10 2008-07-10 Pfizer Inc Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
US20100215580A1 (en) 2006-09-08 2010-08-26 The Johns Hopkins University Compositions and methods for enhancing transport through mucus
GB0619869D0 (en) 2006-10-07 2006-11-15 Regentec Ltd Porous particles
KR20140032505A (ko) 2006-11-09 2014-03-14 알콘 리서치, 리미티드 약물 전달용 수불용성 폴리머 매트릭스
GB0701896D0 (en) 2007-02-01 2007-03-14 Regentec Ltd Composition
EP2121057A4 (en) 2007-02-06 2012-10-10 Incept Llc POLYMERIZATION WITH PRECIPITATION OF PROTEINS FOR ELUTION IN A PHYSIOLOGICAL SOLUTION
US8492334B2 (en) 2007-06-21 2013-07-23 Yale University Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
CN101081206A (zh) * 2007-06-29 2007-12-05 济南康泉医药科技有限公司 一种含酪氨酸激酶抑制剂的抗癌药物组合物
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
US8268342B2 (en) 2007-10-26 2012-09-18 National Institute Of Immunology Biodegradable polymer scaffold and process for preparation thereof
WO2009100176A2 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
EP2255788B1 (en) 2008-02-29 2015-07-22 Nagoya Industrial Science Research Institute Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye
CN101336890A (zh) 2008-05-30 2009-01-07 济南基福医药科技有限公司 一种抗癌缓释凝胶注射剂
US8993615B2 (en) * 2008-08-08 2015-03-31 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
US20100063135A1 (en) 2008-09-10 2010-03-11 Abbott Laboratories Polyethylene glycol lipid conjugates and uses thereof
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
JP2012515014A (ja) 2009-01-12 2012-07-05 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド 組織再生膜
CA3045436C (en) 2009-01-29 2025-10-07 Forsight Vision4, Inc. ADMINISTRATION OF A MEDICATION IN THE POSTERIOR SEGMENT
WO2010091187A2 (en) 2009-02-04 2010-08-12 The Brigham And Women's Hospital, Inc. Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
US8409606B2 (en) 2009-02-12 2013-04-02 Incept, Llc Drug delivery through hydrogel plugs
CA2753690A1 (en) 2009-03-03 2010-09-10 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
GB0903810D0 (en) 2009-03-05 2009-04-22 Regentec Ltd Delivery system
WO2010114770A1 (en) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
EP3583960A1 (en) 2009-12-15 2019-12-25 Incept, LLC Implants and biodegradable fiducial markers
US8889193B2 (en) * 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US20130071349A1 (en) 2010-03-02 2013-03-21 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
WO2011119777A2 (en) * 2010-03-23 2011-09-29 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
US20110237686A1 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
WO2012061703A1 (en) 2010-11-05 2012-05-10 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
WO2012112674A2 (en) * 2011-02-15 2012-08-23 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
CN103127096B (zh) * 2011-12-02 2015-11-25 杨子娇 吡咯基取代的吲哚类化合物在治疗青光眼病的应用
CN104349769B (zh) 2011-12-05 2018-10-09 因赛普特有限责任公司 医用有机凝胶方法和组合物
US20140329913A1 (en) 2011-12-14 2014-11-06 The Johns Hopkins University Nanoparticles with enhanced mucosal penetration or decreased inflammation
KR101811917B1 (ko) 2012-01-19 2017-12-22 더 존스 홉킨스 유니버시티 점액 침투 강화를 나타내는 나노 입자 제형
CA2867203C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
JP5883539B2 (ja) 2012-03-16 2016-03-15 ザ・ジョンズ・ホプキンス・ユニバーシティー Hif−1阻害剤の送達のための放出制御製剤
US20140107025A1 (en) 2012-04-16 2014-04-17 Jade Therapeutics, Llc Ocular drug delivery system
HK1208382A1 (en) * 2012-05-03 2016-03-04 卡拉制药公司 Pharmaceutical nanoparticles showing improved mucosal transport
AU2013256130B2 (en) 2012-05-03 2017-12-21 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
WO2013166498A1 (en) 2012-05-04 2013-11-07 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
US9539259B2 (en) * 2012-05-23 2017-01-10 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
CA2876311A1 (en) * 2012-06-25 2013-12-19 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing sunitinib
CA2885022A1 (en) * 2012-09-17 2014-03-20 Bind Therapeutics, Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
CN103848985B (zh) * 2012-11-30 2018-03-02 杨子剑 含有舒尼替尼类似物结构的新化合物以及制备方法和用途
ES2834964T3 (es) 2013-04-01 2021-06-21 Allergan Inc Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida
CN104208715B (zh) 2013-05-31 2016-12-28 天津键凯科技有限公司 具有提高的药物生物活性的低分子量聚乙二醇药物结合物
JP5698882B1 (ja) 2013-06-18 2015-04-08 昭和電工株式会社 コンデンサ陽極体およびその製造方法
US10646027B2 (en) 2013-08-29 2020-05-12 Sayeeda Mazed Multifunctional personal care devices/apparatuses and compositions for hair or skin
CA2933900A1 (en) 2013-12-20 2015-06-25 Georgia Tech Research Corporation Formulations and methods for targeted ocular delivery of therapeutic agents
KR101564401B1 (ko) 2014-04-10 2015-11-02 한국화학연구원 브린졸아마이드의 제조방법
MX2017001863A (es) 2014-08-13 2017-07-17 Univ Johns Hopkins Nanoparticulas cargadas con glucocorticoides para prevencion de rechazo de aloinjerto corneal y neovascularizacion.
US20160106587A1 (en) 2014-10-16 2016-04-21 Incept, Llc Ocular gels or hydrogels and microinjectors
WO2016065245A1 (en) 2014-10-24 2016-04-28 Incept, Llc Extra luminal scaffold
WO2016094646A1 (en) 2014-12-10 2016-06-16 Incept, Llc Hydrogel drug delivery implants
SG10201903210WA (en) * 2014-12-15 2019-05-30 Univ Johns Hopkins Sunitinib Formulations and Methods for Use Thereof in Treatment of Ocular Disorders
JP6479485B2 (ja) 2015-01-15 2019-03-06 大内新興化学工業株式会社 眼疾患治療用ナノ粒子製剤
WO2016118506A1 (en) 2015-01-20 2016-07-28 The Johns Hopkins University Compositions for the sustained release of anti-glaucoma agents to control intraocular pressure
CN107530334A (zh) 2015-05-05 2018-01-02 普西维达公司 可注射贮库制剂
EP3294212B1 (en) 2015-05-12 2023-10-25 Incept, LLC Drug delivery from hydrogels
CN107949354B (zh) 2015-07-22 2022-02-18 因赛普特有限责任公司 涂覆的泪点塞
JP2018536484A (ja) 2015-11-25 2018-12-13 インセプト・リミテッド・ライアビリティ・カンパニーIncept,Llc 形状変化する薬物送達デバイス及び方法

Similar Documents

Publication Publication Date Title
JP2017537985A5 (cg-RX-API-DMAC7.html)
JP2018500394A5 (cg-RX-API-DMAC7.html)
Kamaleddin Nano-ophthalmology: Applications and considerations
RU2017123358A (ru) Составы на основе сунитиниба и способы их применения для лечения глазных заболеваний
JP2016521712A5 (cg-RX-API-DMAC7.html)
JP2014533698A5 (cg-RX-API-DMAC7.html)
HRP20230510T1 (hr) Farmaceutski pripravak dasatinib
JP2016535777A5 (cg-RX-API-DMAC7.html)
WO2016042163A3 (en) Ophthalmic drug compositions
EA201991299A1 (ru) Приготовление твердых циклодекстриновых комплексов для доставки офтальмологических активных фармацевтических ингредиентов
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
MX2017015250A (es) Formacion de nanoparticulas de ciclosporina a/ciclodextrina.
JP2016528202A5 (cg-RX-API-DMAC7.html)
PH12015502587A1 (en) Opthalmic nanoemulsion composition containing cyclosporine and method for preparing same
HRP20210577T1 (hr) Sastavi i načini liječenja i sprječavanje upale
BR112015019039A8 (pt) compostos antagonistas de integrina fluorados, composição farmacêutica compreendendo ditos compostos e uso destes para tratar ou prevenir uma doença ou condição mediada por uma av integrina
JP2011522792A5 (cg-RX-API-DMAC7.html)
JP2015526467A5 (cg-RX-API-DMAC7.html)
JP2013542205A5 (cg-RX-API-DMAC7.html)
JP2016027060A5 (cg-RX-API-DMAC7.html)
JP2015520241A5 (cg-RX-API-DMAC7.html)
JP2017512194A5 (cg-RX-API-DMAC7.html)
WO2016011297A3 (en) Methods and related compositions for improved drug bioavailability and disease treatment
RU2017112930A (ru) Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза
JP2017525758A5 (cg-RX-API-DMAC7.html)